AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
Effective August 16, 2019, AngioSoma, Inc. (‘The Company’, ‘We’, ‘Our’) filed an amendment to its Form 10-K for the fiscal year ended September 30, 2018 as well as an amendment to the previously filed Form 13D of the President & CEO, Alex Blankenship, to confirm that, effective May 16, 2017 the previously reported sharing of voting control was terminated and voting control unconditionally vests in the President and CEO.
In addition, management remains optimistic about consummation of the acquisition of Diabetes Relief upon the terms of the December 2018 letter of intent because AngioSoma’s patented pharmaceutical, LiprostinTM, is an effective endovascular intervention in the treatment of peripheral artery disease (PAD), usually a result of type II diabetes.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press Release
AngioSoma, Inc. Exhibit
EX-99 2 ex_99-1.htm PRESS RELEASE EXHIBIT 99.1 Angiosoma,…
To view the full exhibit click here
